Cost-effectiveness as an outcome in randomized clinical trials
暂无分享,去创建一个
[1] Bernie J. O'Brien,et al. In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care , 1994, Medical care.
[2] G. Sanders,et al. Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction , 2001, Annals of Internal Medicine.
[3] R. Cappato,et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). , 2000, Circulation.
[4] D. Mark,et al. Medical economics and the assessment of value in cardiovascular medicine: Part I. , 2002, Circulation.
[5] M. Hlatky. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials. , 1999, American heart journal.
[6] Riccardo Cappato,et al. Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Cardiac Arrest The Cardiac Arrest Study Hamburg (CASH) , 2000 .
[7] D. Mark,et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. , 1997, The New England journal of medicine.
[8] James T. Willerson,et al. Appointment of New Associate Editor for Circulation , 1996 .
[9] A. Gotto,et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. , 2000, The American journal of cardiology.
[10] D. Mark,et al. Medical economics and the assessment of value in cardiovascular medicine: Part II. , 2002, Circulation.
[11] Antonio Colombo,et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.
[12] G. Larsen,et al. Cost-Effectiveness of the Implantable Cardioverter-Defibrillator Versus Antiarrhythmic Drugs in Survivors of Serious Ventricular Tachyarrhythmias: Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Economic Analysis Substudy , 2002, Circulation.
[13] Andrew R Willan,et al. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. , 2005, American heart journal.
[14] M C Weinstein,et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. , 2001, American heart journal.
[15] Robert L. Frye,et al. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.
[16] J. McMurray,et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin , 1997, BMJ.
[17] A I Mushlin,et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. , 1998, Circulation.
[18] G. Sanders,et al. Cost-Effectiveness of Implantable Cardioverter Defibrillators Relative to Amiodarone for Prevention of Sudden Cardiac Death , 1997, Annals of Internal Medicine.
[19] M Gent,et al. Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: Results From the Canadian Implantable Defibrillator Study (CIDS) , 2001, Circulation.
[20] Siu Hui,et al. Methods for Comparison of Cost Data , 1997, Annals of Internal Medicine.
[21] Mark A Hlatky,et al. Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Surgery for Multivessel Coronary Artery Disease , 2004, Circulation.
[22] M. Johannesson,et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. , 1997, The New England journal of medicine.